Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
to estimate difference in change in HbA1c from baseline to treatment endpoint (26 weeks) between 2.0 mg exenatide LAR once weekly and insulin glargine QD in patients with type 2 diabetes and inadequate glycemic control using Met alone or in combination with SU. Superiority of exenatide LAR with respect to change in HbA1c will be concluded if the upper limit of the 95% confidence interval for treatment difference is less than zero. Non-inferiority will be concluded if upper limit of the confidence interval is >=0.0% and <0.3%. Hypotheses will be tested hierarchically.
Critère d'inclusion
- Type 2 Diabetes